MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--March 23, 2004--Protein Mechanics, Inc., and Aventis have entered into an agreement to advance the identification, discovery and validation of highly selective, orally available matrix metalloprotease (MMP) inhibitors, a promising new class of drugs for treatment of a broad array of pathologies involving the extracellular matrix.
The large MMP family has been implicated in solid tumor growth, atherosclerosis, rheumatoid arthritis and Alzheimer's disease, as well as in corneal, periodontal and dermatological disorders. However, these closely related targets present significant selectivity challenges when approached with conventional methods. Protein Mechanics will utilize its Imagiro(R) predictive simulation technology to provide Aventis with insights into important aspects of specific target-ligand interaction, including novel binding sites, binding modes, mechanisms of action and induced-fit conformational changes, in order to drive design and optimization of highly selective drug leads.
"Aventis has a strong record of commitment and accomplishment in the development of novel therapeutics for important disease areas, so we are extremely gratified that it has chosen Protein Mechanics as a partner in this effort," said Ken Haas, President and CEO of Protein Mechanics, Inc. "We have been particularly impressed with Aventis' work in selective metalloprotease inhibition and their expertise in applying novel technologies to critical aspects of drug discovery, so we are highly energized by the onset of our collaboration."
Financial terms of the agreement were not disclosed.
About Protein Mechanics
Protein Mechanics is a drug discovery company using ground-breaking predictive simulation technology to design novel small molecule therapeutics against difficult, high value targets. The Company's unique technology allows medicinal chemists to use capabilities such as direct observation of conformational change and rapid determination of binding affinities to discover new mechanisms of action, new binding sites and new compounds or scaffolds. Protein Mechanics intends to pursue certain targets on behalf of corporate pharmaceutical partners using its discovery technology to help generate lead compounds in multiple disease areas. In addition, the Company will selectively pursue other compounds and targets for internal development. Established in 2001, Protein Mechanics, Inc., is a privately held biotechnology company headquartered in Mountain View, California.
For more information, please visit: www.ProteinMechanics.com
Protein Mechanics, Inc. Michael Hollars, 408-472-5655 email@example.com